Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BPV for first-line symptomatic multiple myeloma in transplant-ineligible patients
2013-005485-19Phase 2Completed
- Sponsor
- Heidelberg University Hospital
- Start
- Jul 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bendamustine, prednisone and bortezomib in multiple myeloma (MM), sponsored by Heidelberg University Hospital. Primary endpoint: Overall Response Rate. Started Jul 2014; status: completed.
02
Drugs
bendamustineprednisonebortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2013-005485-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005485-19.